Cancer

Survival and death signals can predict tumor response to therapy after oncogene inactivation

Phuoc T Tran, Pavan K. Bendapudi, H. Jill Lin, Peter Choi, Shan Koh, Joy Chen, George Horng, Nicholas P. Hughes, Lawrence H. Schwartz, Vincent A. Miller, Toshiyuki Kawashima, Toshio Kitamura, David Paik, Dean W. Felsher

Research output: Contribution to journalArticle

Abstract

Cancers can exhibit marked tumor regression after oncogene inhibition through a phenomenon called "oncogene addiction." The ability to predict when a tumor will exhibit oncogene addiction would be useful in the development of targeted therapeutics. Oncogene addiction is likely the consequence of many cellular programs. However, we reasoned that many of these inputs may converge on aggregate survival and death signals. To test this, we examined conditional transgenic models of K-rasG12D- or MYC-induced lung tumors and lymphoma combined with quantitative imaging and an in situ analysis of biomarkers of proliferation and apoptotic signaling. We then used computational modeling based on ordinary differential equations (ODEs) to show that oncogene addiction could be modeled as differential changes in survival and death intracellular signals. Our mathematical model could be generalized to different imaging methods (computed tomography and bioluminescence imaging), different oncogenes (K-rasG12D and MYC), and several tumor types (lung and lymphoma). Our ODE model could predict the differential dynamics of several putative prosurvival and prodeath signaling factors [phosphorylated extracellular signal-regulated kinase 1 and 2, Akt1, Stat3/5 (signal transducer and activator of transcription 3/5), and p38] that contribute to the aggregate survival and death signals after oncogene inactivation. Furthermore, we could predict the influence of specific genetic lesions (p53-/-, Stat3-d358L, and myr-Akt1) on tumor regression after oncogene inactivation. Then, using machine learning based on support vector machine, we applied quantitative imaging methods to human patients to predict both their EGFR genotype and their progression-free survival after treatment with the targeted therapeutic erlotinib. Hence, the consequences of oncogene inactivation can be accurately modeled on the basis of a relatively small number of parameters that may predict when targeted therapeutics will elicit oncogene addiction after oncogene inactivation and hence tumor regression.

Original languageEnglish (US)
JournalScience Translational Medicine
Volume3
Issue number103
DOIs
StatePublished - Oct 5 2011

Fingerprint

Oncogenes
Neoplasms
Therapeutics
Survival
Lymphoma
STAT5 Transcription Factor
STAT3 Transcription Factor
Lung
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Disease-Free Survival
Theoretical Models
Biomarkers
Genotype
Tomography

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cancer : Survival and death signals can predict tumor response to therapy after oncogene inactivation. / Tran, Phuoc T; Bendapudi, Pavan K.; Lin, H. Jill; Choi, Peter; Koh, Shan; Chen, Joy; Horng, George; Hughes, Nicholas P.; Schwartz, Lawrence H.; Miller, Vincent A.; Kawashima, Toshiyuki; Kitamura, Toshio; Paik, David; Felsher, Dean W.

In: Science Translational Medicine, Vol. 3, No. 103, 05.10.2011.

Research output: Contribution to journalArticle

Tran, PT, Bendapudi, PK, Lin, HJ, Choi, P, Koh, S, Chen, J, Horng, G, Hughes, NP, Schwartz, LH, Miller, VA, Kawashima, T, Kitamura, T, Paik, D & Felsher, DW 2011, 'Cancer: Survival and death signals can predict tumor response to therapy after oncogene inactivation', Science Translational Medicine, vol. 3, no. 103. https://doi.org/10.1126/scitranslmed.3002018
Tran, Phuoc T ; Bendapudi, Pavan K. ; Lin, H. Jill ; Choi, Peter ; Koh, Shan ; Chen, Joy ; Horng, George ; Hughes, Nicholas P. ; Schwartz, Lawrence H. ; Miller, Vincent A. ; Kawashima, Toshiyuki ; Kitamura, Toshio ; Paik, David ; Felsher, Dean W. / Cancer : Survival and death signals can predict tumor response to therapy after oncogene inactivation. In: Science Translational Medicine. 2011 ; Vol. 3, No. 103.
@article{d295f10a22ef4e4dbb4072366c630607,
title = "Cancer: Survival and death signals can predict tumor response to therapy after oncogene inactivation",
abstract = "Cancers can exhibit marked tumor regression after oncogene inhibition through a phenomenon called {"}oncogene addiction.{"} The ability to predict when a tumor will exhibit oncogene addiction would be useful in the development of targeted therapeutics. Oncogene addiction is likely the consequence of many cellular programs. However, we reasoned that many of these inputs may converge on aggregate survival and death signals. To test this, we examined conditional transgenic models of K-rasG12D- or MYC-induced lung tumors and lymphoma combined with quantitative imaging and an in situ analysis of biomarkers of proliferation and apoptotic signaling. We then used computational modeling based on ordinary differential equations (ODEs) to show that oncogene addiction could be modeled as differential changes in survival and death intracellular signals. Our mathematical model could be generalized to different imaging methods (computed tomography and bioluminescence imaging), different oncogenes (K-rasG12D and MYC), and several tumor types (lung and lymphoma). Our ODE model could predict the differential dynamics of several putative prosurvival and prodeath signaling factors [phosphorylated extracellular signal-regulated kinase 1 and 2, Akt1, Stat3/5 (signal transducer and activator of transcription 3/5), and p38] that contribute to the aggregate survival and death signals after oncogene inactivation. Furthermore, we could predict the influence of specific genetic lesions (p53-/-, Stat3-d358L, and myr-Akt1) on tumor regression after oncogene inactivation. Then, using machine learning based on support vector machine, we applied quantitative imaging methods to human patients to predict both their EGFR genotype and their progression-free survival after treatment with the targeted therapeutic erlotinib. Hence, the consequences of oncogene inactivation can be accurately modeled on the basis of a relatively small number of parameters that may predict when targeted therapeutics will elicit oncogene addiction after oncogene inactivation and hence tumor regression.",
author = "Tran, {Phuoc T} and Bendapudi, {Pavan K.} and Lin, {H. Jill} and Peter Choi and Shan Koh and Joy Chen and George Horng and Hughes, {Nicholas P.} and Schwartz, {Lawrence H.} and Miller, {Vincent A.} and Toshiyuki Kawashima and Toshio Kitamura and David Paik and Felsher, {Dean W.}",
year = "2011",
month = "10",
day = "5",
doi = "10.1126/scitranslmed.3002018",
language = "English (US)",
volume = "3",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "103",

}

TY - JOUR

T1 - Cancer

T2 - Survival and death signals can predict tumor response to therapy after oncogene inactivation

AU - Tran, Phuoc T

AU - Bendapudi, Pavan K.

AU - Lin, H. Jill

AU - Choi, Peter

AU - Koh, Shan

AU - Chen, Joy

AU - Horng, George

AU - Hughes, Nicholas P.

AU - Schwartz, Lawrence H.

AU - Miller, Vincent A.

AU - Kawashima, Toshiyuki

AU - Kitamura, Toshio

AU - Paik, David

AU - Felsher, Dean W.

PY - 2011/10/5

Y1 - 2011/10/5

N2 - Cancers can exhibit marked tumor regression after oncogene inhibition through a phenomenon called "oncogene addiction." The ability to predict when a tumor will exhibit oncogene addiction would be useful in the development of targeted therapeutics. Oncogene addiction is likely the consequence of many cellular programs. However, we reasoned that many of these inputs may converge on aggregate survival and death signals. To test this, we examined conditional transgenic models of K-rasG12D- or MYC-induced lung tumors and lymphoma combined with quantitative imaging and an in situ analysis of biomarkers of proliferation and apoptotic signaling. We then used computational modeling based on ordinary differential equations (ODEs) to show that oncogene addiction could be modeled as differential changes in survival and death intracellular signals. Our mathematical model could be generalized to different imaging methods (computed tomography and bioluminescence imaging), different oncogenes (K-rasG12D and MYC), and several tumor types (lung and lymphoma). Our ODE model could predict the differential dynamics of several putative prosurvival and prodeath signaling factors [phosphorylated extracellular signal-regulated kinase 1 and 2, Akt1, Stat3/5 (signal transducer and activator of transcription 3/5), and p38] that contribute to the aggregate survival and death signals after oncogene inactivation. Furthermore, we could predict the influence of specific genetic lesions (p53-/-, Stat3-d358L, and myr-Akt1) on tumor regression after oncogene inactivation. Then, using machine learning based on support vector machine, we applied quantitative imaging methods to human patients to predict both their EGFR genotype and their progression-free survival after treatment with the targeted therapeutic erlotinib. Hence, the consequences of oncogene inactivation can be accurately modeled on the basis of a relatively small number of parameters that may predict when targeted therapeutics will elicit oncogene addiction after oncogene inactivation and hence tumor regression.

AB - Cancers can exhibit marked tumor regression after oncogene inhibition through a phenomenon called "oncogene addiction." The ability to predict when a tumor will exhibit oncogene addiction would be useful in the development of targeted therapeutics. Oncogene addiction is likely the consequence of many cellular programs. However, we reasoned that many of these inputs may converge on aggregate survival and death signals. To test this, we examined conditional transgenic models of K-rasG12D- or MYC-induced lung tumors and lymphoma combined with quantitative imaging and an in situ analysis of biomarkers of proliferation and apoptotic signaling. We then used computational modeling based on ordinary differential equations (ODEs) to show that oncogene addiction could be modeled as differential changes in survival and death intracellular signals. Our mathematical model could be generalized to different imaging methods (computed tomography and bioluminescence imaging), different oncogenes (K-rasG12D and MYC), and several tumor types (lung and lymphoma). Our ODE model could predict the differential dynamics of several putative prosurvival and prodeath signaling factors [phosphorylated extracellular signal-regulated kinase 1 and 2, Akt1, Stat3/5 (signal transducer and activator of transcription 3/5), and p38] that contribute to the aggregate survival and death signals after oncogene inactivation. Furthermore, we could predict the influence of specific genetic lesions (p53-/-, Stat3-d358L, and myr-Akt1) on tumor regression after oncogene inactivation. Then, using machine learning based on support vector machine, we applied quantitative imaging methods to human patients to predict both their EGFR genotype and their progression-free survival after treatment with the targeted therapeutic erlotinib. Hence, the consequences of oncogene inactivation can be accurately modeled on the basis of a relatively small number of parameters that may predict when targeted therapeutics will elicit oncogene addiction after oncogene inactivation and hence tumor regression.

UR - http://www.scopus.com/inward/record.url?scp=80053649037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053649037&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3002018

DO - 10.1126/scitranslmed.3002018

M3 - Article

VL - 3

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 103

ER -